Healio

Laru-zova shows safety, low luminance visual acuity gains in X-linked retinitis pigmentosa

Please provide your email address to receive an email when new articles are posted on . Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in ...

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key ...
Ophthalmology Times

Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

RevitalVision, a Digital Therapeutic, Demonstrates Efficacy and Safety in Infantile Nystagmus

RevitalVision is an FDA-cleared perceptual learning software program that has been clinically validated to improve vision in several eye diseases and vision conditions--such as adult amblyopia, ...
Medscape

Visual Acuity Screening May Not Improve Outcomes in Older Adults

July 15, 2009 — Current evidence is insufficient to determine the balance of benefits and harms of visual acuity screening for the improvement of outcomes in older adults, according to a position ...
Pharmabiz

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Oculis Holding AG: Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...